| BRCA mutations in prostate cancer: prognostic and predictive implications C Messina, C Cattrini, D Soldato, G Vallome, O Caffo, E Castro, D Olmos, ... Journal of oncology 2020, 2020 | 93 | 2020 |
| Genetic aberrations in DNA repair pathways: A cornerstone of precision oncology in prostate cancer R Lozano, E Castro, IM Aragón, Y Cendón, C Cattrini, PP López-Casas, ... British journal of cancer 124 (3), 552-563, 2021 | 85 | 2021 |
| Current treatment options for metastatic hormone-sensitive prostate cancer C Cattrini, E Castro, R Lozano, E Zanardi, A Rubagotti, F Boccardo, ... Cancers 11 (9), 1355, 2019 | 76 | 2019 |
| Sex hormones and hormone therapy during COVID-19 pandemic: implications for patients with cancer C Cattrini, M Bersanelli, MM Latocca, B Conte, G Vallome, F Boccardo Cancers 12 (8), 2325, 2020 | 72 | 2020 |
| CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials C Messina, C Cattrini, G Buzzatti, L Cerbone, E Zanardi, M Messina, ... Breast cancer research and treatment 172, 9-21, 2018 | 69 | 2018 |
| Role of circulating tumor cells (CTC), androgen receptor full length (AR-FL) and androgen receptor splice variant 7 (AR-V7) in a prospective cohort of castration-resistant … C Cattrini, A Rubagotti, L Zinoli, L Cerbone, E Zanardi, M Capaia, ... Cancers 11 (9), 1365, 2019 | 33 | 2019 |
| Insulin/IGF axis in breast cancer: clinical evidence and translational insights F Biello, F Platini, F D’avanzo, C Cattrini, A Mennitto, S Genestroni, ... Biomolecules 11 (1), 125, 2021 | 32 | 2021 |
| Targeting androgen-independent pathways: new chances for patients with prostate cancer? C Cattrini, E Zanardi, G Vallome, A Cavo, L Cerbone, A Di Meglio, ... Critical Reviews in Oncology/Hematology 118, 42-53, 2017 | 31 | 2017 |
| Optimal sequencing and predictive biomarkers in patients with advanced prostate cancer C Cattrini, R España, A Mennitto, M Bersanelli, E Castro, D Olmos, ... Cancers 13 (18), 4522, 2021 | 28 | 2021 |
| Epidemiological characteristics and survival in patients with de novo metastatic prostate cancer C Cattrini, D Soldato, A Rubagotti, L Zinoli, E Zanardi, P Barboro, ... Cancers 12 (10), 2855, 2020 | 22 | 2020 |
| Apalutamide, darolutamide and enzalutamide for nonmetastatic castration-resistant prostate cancer (nmCRPC): a critical review C Cattrini, O Caffo, U De Giorgi, A Mennitto, A Gennari, D Olmos, E Castro Cancers 14 (7), 1792, 2022 | 20 | 2022 |
| A hnRNP K–AR-related signature reflects progression toward castration-resistant prostate cancer M Capaia, I Granata, M Guarracino, A Petretto, E Inglese, C Cattrini, ... International Journal of Molecular Sciences 19 (7), 1920, 2018 | 20 | 2018 |
| SARS‐CoV‐2 reinfection in a cancer patient with a defective neutralizing humoral response C Borgogna, M De Andrea, G Griffante, A Lai, A Bergna, M Galli, ... Journal of medical virology 93 (12), 6444, 2021 | 19 | 2021 |
| Etoposide and topoisomerase II inhibition for aggressive prostate cancer: Data from a translational study. C Cattrini, M Capaia, F Boccardo, P Barboro Cancer treatment and research communications 25, 100221, 2020 | 18 | 2020 |
| Abiraterone acetate and prednisone in the pre-and post-docetaxel setting for metastatic castration-resistant prostate cancer: a mono-institutional experience focused on … A Cavo, A Rubagotti, E Zanardi, C Fabbroni, L Zinoli, A Di Meglio, ... Therapeutic advances in medical oncology 10, 1758834017745819, 2018 | 17 | 2018 |
| Addition of androgen receptor-targeted agents to androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis BA Maiorano, U De Giorgi, G Roviello, C Messina, A Altavilla, C Cattrini, ... ESMO open 7 (5), 100575, 2022 | 16 | 2022 |
| Atezolizumab and bladder cancer: facing a complex disease C Cattrini, F Boccardo The Lancet 391 (10118), 305-306, 2018 | 15 | 2018 |
| Medical liability in cancer care during COVID-19 pandemic: heroes or guilty? R Barranco, C Messina, A Bonsignore, C Cattrini, F Ventura Frontiers in Public Health 8, 602988, 2020 | 14 | 2020 |
| Presence of somatic/germline homologous recombination repair (HRR) mutations and outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) receiving … D Olmos, D Lorente, D Alameda, C Cattrini, N Romero-Laorden, ... Journal of Clinical Oncology 41 (16_suppl), 5003-5003, 2023 | 13 | 2023 |
| Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysis C Cattrini, C Messina, C Airoldi, S Buti, G Roviello, A Mennitto, O Caffo, ... Therapeutic Advances in Urology 13, 17562872211053189, 2021 | 13 | 2021 |
Paola BarboroDirigente BiologoVerified email at hsanmartino.it
